187 related articles for article (PubMed ID: 30344523)
1. Development of a Stable MGAT1
Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW
Front Immunol; 2018; 9():2313. PubMed ID: 30344523
[TBL] [Abstract][Full Text] [Related]
2. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
[TBL] [Abstract][Full Text] [Related]
3. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
Yu B; Morales JF; O'Rourke SM; Tatsuno GP; Berman PW
PLoS One; 2012; 7(8):e43903. PubMed ID: 22928048
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.
Byrne G; O'Rourke SM; Alexander DL; Yu B; Doran RC; Wright M; Chen Q; Azadi P; Berman PW
PLoS Biol; 2018 Aug; 16(8):e2005817. PubMed ID: 30157178
[TBL] [Abstract][Full Text] [Related]
5. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
7. Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.
Zambonelli C; Dey AK; Hilt S; Stephenson S; Go EP; Clark DF; Wininger M; Labranche C; Montefiori D; Liao HX; Swanstrom RI; Desaire H; Haynes BF; Carfi A; Barnett SW
PLoS One; 2016; 11(7):e0157391. PubMed ID: 27442017
[TBL] [Abstract][Full Text] [Related]
8. Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.
Li SW; Yu B; Byrne G; Wright M; O'Rourke S; Mesa K; Berman PW
Biotechnol Bioeng; 2019 Sep; 116(9):2130-2145. PubMed ID: 31087560
[TBL] [Abstract][Full Text] [Related]
9. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
[TBL] [Abstract][Full Text] [Related]
10. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.
Smith DH; Winters-Digiacinto P; Mitiku M; O'Rourke S; Sinangil F; Wrin T; Montefiori DC; Berman PW
PLoS One; 2010 Aug; 5(8):e12076. PubMed ID: 20711452
[TBL] [Abstract][Full Text] [Related]
12. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
J Virol; 2017 May; 91(9):. PubMed ID: 28202756
[TBL] [Abstract][Full Text] [Related]
14. Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production.
O'Rourke SM; Byrne G; Tatsuno G; Wright M; Yu B; Mesa KA; Doran RC; Alexander D; Berman PW
PLoS One; 2018; 13(8):e0197656. PubMed ID: 30071025
[TBL] [Abstract][Full Text] [Related]
15. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
Morales JF; Morin TJ; Yu B; Tatsuno GP; O'Rourke SM; Theolis R; Mesa KA; Berman PW
J Biol Chem; 2014 Jul; 289(30):20526-42. PubMed ID: 24872420
[TBL] [Abstract][Full Text] [Related]
17. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
[TBL] [Abstract][Full Text] [Related]
18. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
[TBL] [Abstract][Full Text] [Related]
19. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.
Panico M; Bouché L; Binet D; O'Connor MJ; Rahman D; Pang PC; Canis K; North SJ; Desrosiers RC; Chertova E; Keele BF; Bess JW; Lifson JD; Haslam SM; Dell A; Morris HR
Sci Rep; 2016 Sep; 6():32956. PubMed ID: 27604319
[TBL] [Abstract][Full Text] [Related]
20. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
